Tumour cells could be used to develop personalised light-activated cancer vaccines

Cancer Research UK

Cancer tissue taken directly from patients could be used to produce a light-triggered vaccine to target and treat their own tumours, according to a study published in the British Journal of Cancer* today (Tuesday).

Photodynamic therapy (PDT) is a type of treatment that can be used to treat some types of cancer and works by activating a light-sensitive drug. Research has recently shown that PDT can also stimulate an immune response against a tumour.

Now researchers based at the British Columbia Cancer Agency in Vancouver, Canada, have developed this interesting technique further. The authors performed PDT on mouse tumour samples in the laboratory and injected them back into the same mice. This new technique was as effective as using cancer cells grown in the laboratory in the vaccine, but cuts out the time-consuming process of culturing cells and allows the treatment to home in on unique characteristics of the individual's tumour.

Using a sample of the patient's own cancer will in theory allow the treatment to be personalised to the individual patient by acting against proteins specific to the tumour and capitalise on the increased immune response from cells used in the vaccine.

Dr Mladen Korbelik, senior author of the paper, said: "The prospect of using samples from a patient's own tumour to treat them is really exciting. This technique could mean that treatment is delivered more quickly and, most importantly, is tailored to the individual's cancer.

"Although our results showed this method produces powerful cancer vaccines, we're confident that this technique can be advanced further to be even more potent and effective."

Dr Lesley Walker, director of cancer information at Cancer Research UK, which owns the British Journal of Cancer, said: "This is an interesting application of PDT. Using targeted treatments with better delivery and manipulating the body's own immune system to fight the disease means patients would experience fewer side effects. Although this type of vaccine is in its early stages, developing existing techniques in this way could provide us with more effective treatments in the future."

ENDS

For media enquiries please contact the press office on 020 7061 8252 or, out-of-hours, the duty press officer on 07050 264 059.

Notes to Editor

*Korbelik et al. British Journal of Cancer, Volume 97, Issue 10.

British Journal of Cancer

The BJC's mission is to encourage communication of the very best cancer research from laboratories and clinics in all countries. Broad coverage, its editorial independence and consistent high standards have made BJC one of the world's premier general cancer journals.

About Cancer Research UK

  • Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
  • Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
  • Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
  • Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
  • Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
  • For further information about Cancer Research UK's work or to find out how to support the charity, please call 020 7009 8820 or visit our homepage.